Low Serum Prestin Emerges as a Potential Biomarker for Sudden Hearing Loss: Study
A recent cross-sectional study published in the International Journal of Otorhinolaryngology and Head and Neck Surgery in August 2026 reveals an exciting breakthrough for rapidly and objectively diagnosing sudden hearing loss. It demonstrates that blood levels of a specific inner ear motor protein dipping below a critical threshold of 450.7 pg/ml could be the missing diagnostic key.
While sudden hearing loss is traditionally diagnosed through subjective tests, the inner ear protein prestin shows great promise as an objective biological marker. To bridge the gap of missing clinical thresholds, Dr. Pranitasari and colleagues investigated the exact diagnostic role of serum prestin for this condition.
Therefore, a study evaluated blood prestin levels in 13 sudden hearing loss patients and 12 healthy controls to determine a normal diagnostic threshold and assess predictive risk. To guarantee accurate results, participants with preexisting ear conditions, past surgeries, or extreme noise exposure were strictly excluded.
Key Clinical Findings of the Study Includes:
Optimal Diagnostic Threshold: Researchers identified a normal serum prestin cutoff value of 450.7 pg/ml to effectively distinguish between the affected and healthy clinical groups.
Prevalence in Cases: The analysis convincingly revealed that a significant majority, specifically 84.6%, of the patients diagnosed with SSNHL exhibited low serum prestin levels falling below the established clinical threshold.
Comparison to Healthy Controls: Conversely, 58.3% of the healthy control participants demonstrated normal, high serum prestin concentrations safely at or above the 450.7 pg/ml mark.
Significant Risk Association: Low prestin concentrations were robustly shown to substantially increase the likelihood of hearing loss, presenting an odds ratio of 7.7 when compared directly to those patients with higher baseline levels.
Independent Predictive Value: After statistically adjusting for potential confounding variables such as patient age and gender, diminished serum prestin remained a remarkably potent independent predictor of the condition with an adjusted odds ratio of 15.4.
The results suggest that an abnormally low serum prestin concentration, specifically dipping below the meticulously identified 450.7 pg/ml cut-off, exponentially increases the inherent risk of sudden hearing impairment. This prominent molecular reduction establishes the outer hair cell protein as a highly promising and practical clinical biomarker for rapid, objective diagnosis.
Thus, the study concludes that integrating routine serum prestin measurements into standard clinical practice could potentially serve as a highly valuable adjunctive tool for healthcare providers to objectively detect and manage cochlear outer hair cell damage much earlier in the disease progression.
While restricted by a relatively small participant sample size, mismatched demographic age distributions between the comparative groups, and etiologically diverse hearing loss presentations, this foundational clinical work gently highlights the exciting opportunity for larger, age-matched future investigations focusing strictly on idiopathic presentations to further illuminate the diagnostic and prognostic power of this novel biomarker.
Reference
Pranitasari NPOR, Lesmana IWL, Wiranadha M, Sutirtayasa IW, Handayani PN. Low serum prestin level as a potential biomarker for sudden sensorineural hearing loss: a cross-sectional study. Int J Otorhinolaryngol Head Neck Surg 2026;12:512-7.
